Molecular beacon based assay for the detection of biomarkers for breast cancer metastasis
US9297047B2 · kind B2 · utility
Inventors
Key dates
| Filing date | Oct 23, 2012 |
| Grant date | Mar 29, 2016 |
| Priority date | — |
| Expiry date | Dec 3, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The invention encompasses molecular beacon (MB) probes for monitoring the presence of human breast cancer biomarkers and for the analysis of breast cancer metastasis. The molecular beacon is an oligonucleotide probe which sensitively and specifically identifies biomarker mRNA in samples, in the presence of serum, in minimal time using fluorescence detection. The molecular beacons may be comprised in kits for the detection/quantitation of cancer biomarkers in clinical samples. The invention provides improvements in simplicity, accuracy, and speed over current methods, which could allow for improved patient treatment and prognoses.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.